bluebird bio (NASDAQ:BLUE) Now Covered by StockNews.com

StockNews.com started coverage on shares of bluebird bio (NASDAQ:BLUE) in a research report sent to investors on Thursday. The firm issued a sell rating on the biotechnology company’s stock.

Other equities research analysts have also issued research reports about the stock. Wells Fargo & Company cut their target price on shares of bluebird bio from $40.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Monday, February 24th. Baird R W downgraded shares of bluebird bio from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 21st. JPMorgan Chase & Co. upgraded shares of bluebird bio from an “underweight” rating to a “neutral” rating in a research note on Monday, February 24th. Finally, Barclays increased their price objective on shares of bluebird bio from $2.00 to $40.00 and gave the company an “overweight” rating in a research report on Tuesday, December 31st. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $51.00.

bluebird bio Price Performance

Shares of bluebird bio stock opened at $3.90 on Thursday. The company’s fifty day simple moving average is $5.97 and its two-hundred day simple moving average is $8.00. The firm has a market cap of $37.92 million, a PE ratio of -0.10 and a beta of 0.76. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37. bluebird bio has a 12-month low of $3.56 and a 12-month high of $28.60.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its stake in shares of bluebird bio by 3.7% in the third quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock worth $2,433,000 after purchasing an additional 166,771 shares in the last quarter. State Street Corp increased its stake in shares of bluebird bio by 1.1% in the third quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock worth $1,996,000 after purchasing an additional 43,382 shares in the last quarter. FMR LLC grew its stake in bluebird bio by 8.1% during the third quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company’s stock valued at $1,289,000 after acquiring an additional 186,903 shares in the last quarter. BNP Paribas Financial Markets grew its stake in bluebird bio by 2,270.2% during the third quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock valued at $193,000 after acquiring an additional 355,562 shares in the last quarter. Finally, Barclays PLC grew its stake in bluebird bio by 273.7% during the third quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock valued at $130,000 after acquiring an additional 184,605 shares in the last quarter. 87.43% of the stock is currently owned by institutional investors.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.